Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Income: 2021-2024

Historic Net Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Net Income fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • ARS Pharmaceuticals' Net Income amounted to $8.0 million in FY2024, which was up 114.71% from -$54.4 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Net Income peaked at $8.0 million during FY2024, and registered a low of -$54.4 million during FY2023.
  • In the last 3 years, ARS Pharmaceuticals' Net Income had a median value of -$35.5 million in 2022 and averaged -$27.3 million.
  • In the last 5 years, ARS Pharmaceuticals' Net Income crashed by 82.56% in 2022 and then surged by 114.71% in 2024.
  • ARS Pharmaceuticals' Net Income (Yearly) stood at -$19.5 million in 2021, then crashed by 82.56% to -$35.5 million in 2022, then crashed by 53.07% to -$54.4 million in 2023, then skyrocketed by 114.71% to $8.0 million in 2024.